The 36-month beta value for COGT is at 1.97. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for COGT is 95.39M, and currently, shorts hold a 13.63% of that float. The average trading volume for COGT on April 10, 2025 was 1.45M shares.
COGT) stock’s latest price update
Cogent Biosciences Inc (NASDAQ: COGT) has seen a decline in its stock price by -9.19 in relation to its previous close of 4.46. However, the company has experienced a -24.02% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-25 that Four abstracts accepted for poster presentation highlight Cogent’s expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent’s expertise in pioneering best-in-class therapeutics
COGT’s Market Performance
Cogent Biosciences Inc (COGT) has experienced a -24.02% fall in stock performance for the past week, with a -46.64% drop in the past month, and a -50.06% drop in the past quarter. The volatility ratio for the week is 15.92%, and the volatility levels for the past 30 days are at 8.72% for COGT. The simple moving average for the past 20 days is -33.77% for COGT’s stock, with a -55.09% simple moving average for the past 200 days.
Analysts’ Opinion of COGT
Many brokerage firms have already submitted their reports for COGT stocks, with Scotiabank repeating the rating for COGT by listing it as a “Sector Outperform.” The predicted price for COGT in the upcoming period, according to Scotiabank is $17 based on the research report published on March 07, 2025 of the current year 2025.
Robert W. Baird gave a rating of “Neutral” to COGT, setting the target price at $8 in the report published on February 26th of the previous year.
COGT Trading at -44.02% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.88% of loss for the given period.
Volatility was left at 8.72%, however, over the last 30 days, the volatility rate increased by 15.92%, as shares sank -44.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.29% lower at present.
During the last 5 trading sessions, COGT fell by -23.73%, which changed the moving average for the period of 200-days by -54.27% in comparison to the 20-day moving average, which settled at $6.12. In addition, Cogent Biosciences Inc saw -48.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COGT starting from Pinnow Cole, who purchase 43,750 shares at the price of $7.60 back on Jan 14 ’25. After this action, Pinnow Cole now owns 45,848 shares of Cogent Biosciences Inc, valued at $332,412 using the latest closing price.
Stock Fundamentals for COGT
The total capital return value is set at -1.01. Equity return is now at value -99.54, with -79.79 for asset returns.
Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.9.
Currently, EBITDA for the company is -275.94 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
In conclusion, Cogent Biosciences Inc (COGT) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
